‘Arthritis’ nomenclature in the daily practice Luc De Clercq, MD.

Slides:

Advertisements

Similar presentations

Nombres complexes: Module et argument. 11 questions. 20 secondes par question.

Advertisements

1 Copyright © 2013 Elsevier Inc. All rights reserved. Chapter 28.

Defining Remission in Rheumatoid Arthritis. Part 1: Why is a new remission definition in rheumatoid arthritis needed?

DAS 28 in clinical practice

ACR Criteria in Determining Progression of RA StageClinical and Radiologic Criteria Stage 1Early RA No destructive changes observed upon roentgenographic.

Mindanao, Malvin Ace D Reflection on rheumatoid arthritis.

Orientation Session October 28, 2013 AN ESSENTIAL SKILL! 4. Project and E-Learning Program Overview Doc. #: 4.

The Effect of Peloid Application in Out-patient Setting on Knee Osteoarthritis Results of a Pilot Study E Odabaşı, R Tekin, H Erdem, İ.Şimşek, M Turan.

Psoriatic Arthritis Emily Chang Morning Report August 14, 2009 August.

Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,

Emirates Transport Suppliers Excellence Award Emirates Transport Purchasing Department 2014.

Treatment Management of Rheumatoid Arthritis. Findings and In Depth Analysis.

Table 1. Comparison between the provisional diagnosis based on the proforma versus final diagnosis Early arthritis Rheumatoid arthritis 3 6 Psoriatic.

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Psoriatic Arthritis Maggie Davis Hovda Am report 2/16/2010.

Exercise in Ankylosing Spondylitis Prof. Pál Géher MD.

Psoriatic arthritis – definition and classification criteria Philip Helliwell Senior Lecturer in Rheumatology University of Leeds.

Elizabeth Karlson, MD Associate Professor of Medicine

Non-Radiographic Spondyloarthritis Has Greater Work Instability than Other Spondyloarthritis Subtypes in a National Database Sherry Rohekar 1, Robert D.

PsA: Review of Available Assessment Instruments and Lessons from Trial Results Part II Christian Antoni Friedrich Alexander University Erlangen-Nürnberg.

OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Philip Helliwell, Arthur Kavanaugh, Gerry Krueger, Peter.

Yusuf Yazıcı, MD NYU Hospital for Joint Diseases, New York

EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.

Rheumatology teaching session GP ST2 year 8/9/10.

1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.

Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)

Consultant Rheumatologist

Outcome Measures in PsA Philip Mease MD Seattle, WA.

GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.

The Value of Reference Case Methods for Resource Allocation Decision Making Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics.

IMAGING NEURAL CORRELATES OF FATIGUE & PAIN IN PATIENTS WITH RA TREATED WITH TNF INHIBITORS FARHAN BARI SPR RHEUMATOLOGY WARN CONFERENCE 22 ND MAY 2014.

PACE (Psoriatic Arthritis Costs Evaluation Study) (Psoriatic Arthritis Costs Evaluation Study)

Identifying Early Inflammatory Arthritis

Professor, Rheumatology Division, Ankara University Medical Faculty

Volume 18, Issue 2, Pages (March 2015)

Disease Activity Scales in Patients with UPIA

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

Dr Philippe RONDEAUX Chef de Clinique RHUMATOLOGIE ISPPC

Chief investigator- Dr. Kripasindhu Gantait, Associate Professor

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Diagnosing Rheumatoid Arthritis Early

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.

Figure 2 Overlap of associated loci among five rheumatic diseases

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Figure 1 Simplified EULAR and GRAPPA

Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

Updates in RA, PsA, and Biosimilars

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Univariate predictors of (A) ASDAS ID (<1

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Clinical response in patients with early and established RA at month 24. *p

Percentage of patients with RA achieving DAS28(CRP)<2

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Characteristics of the included trials on non-pharmacological treatment. Characteristics of the included trials on non-pharmacological treatment. ASDAS,

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,

Satisfaction with control of RA

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Multivariable model of adjusted

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Presentation transcript:

‘Arthritis’ nomenclature in the daily practice Luc De Clercq, MD

Nomenclature for Arthritis Care The K55 nomenclature offers broad perspectives for new initiatives Diversification; individually adaptable Direct correlation between amount of provided care and financial support But also with direct, new responsibilities –Financial support must finally lead to better care for the patient with arthritis

K55 Arthritis Nomenclature Publication B.S. / M.B.: Applicable: K55 ; Art. 20 § 1 g (= rheumatology) (amb.) – (hosp.) Honorary: 61,77 euro (100% reimbursement for all categories) Max: 2 x / year (cum. with consultation)

K55 Arthritis Nomenclature Standaardevaluatie van het actief ziekteproces, de evolutie en de prognose, door de geaccrediteerde geneesheer-specialist voor reumatologie, bij een patiënt met chronisch inflammatoir reumatisch lijden, met behandelingsplan en schriftelijk verslag aan de huisarts’ Evaluation standard par le médecin spécialiste en rhumatologie accrédité du processus actif de la maladie, de l'évolution et du pronostic, chez un patient avec une pathologie inflammatoire rhumatoïde, avec plan de traitement et rapport écrit au généraliste

K55 Arthritis Nomenclature Patients with –Rheumatoid Arthritis (RA) –Ankylosing Spondylitis (AS) –Psoriatic Arthritis (PsA) DMARD and / or Biological treatment ‘Standard-evaluation’  Patient File Report to generalist

K55 Arthritis Nomenclature Standard evaluation consists of : –Specific Assessment > Care provider > Patient –Global interpretation – ‘reflection’ Confrontation with other findings (Biology, X ray, US, ….) Disease Activity, Evolution, Prognosis Analysis / Definition / Refining of therapeutic plan

K55 Arthritis Nomenclature Specific Assessment: –For RA: DAS 28 + HAQ –For AS BASFI + BASDAI –For PsA PsARC + HAQ (poly) / NRS scale (pauci)

PsARC : Psoriatic Arthritis Response Criteria Physician’s global assessment (0-5) Patient’s global self-assessment (0-5) Joint tenderness Joint swelling You will obtain a ‘set’ of 4 ‘results’. You will not have a ‘composite’ score

PsARC : Psoriatic Arthritis Response Criteria Treatment response = Improvement in at least 2 of 4 criteria –one must be joint tenderness or swelling –with no worsening in the others 1 and 2 : –improvement decrease > 1 unit –worsening increase > 1 unit 3 and 4 : –improvement decrease > 30% –worsening increase > 30 %

BASFI

DAS 28 DAS 28 = 0,56*√(TJC28)+ 0,28*√(SJC28)+ 0,7*LN(ESR)+ 0,014*VAS GA Patient

We look forwards ….